An anti-tumor compound and its preparation method and application

By fermenting the activated cyanobacter ZHS32 in solid culture medium and leaching with ethyl acetate, an anti-hepatitis cancer compound was successfully purified, solving the problem of poor therapeutic effect of existing anti-tumor drugs on liver cancer cells, and achieving liver cancer Effective inhibition of cells.

CN115677717BActive Publication Date: 2024-11-12INST OF MICROBIOLOGY CHINESE ACAD OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110847735.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-07-27
Publication Date
2024-11-12
Estimated Expiration
2041-07-27

AI Technical Summary

Technical Problem

Existing anti-tumor drugs have limited therapeutic effects on liver cancer cells and lack natural product compounds with significant activity and unique structure.

Method used

A anti-hepatic cancer compound was obtained by fermenting Talaromyces sp. ZHS32 in solid medium, leaching with ethyl acetate and isolation and purification by reduced pressure silica gel column chromatography, reverse phase column chromatography and HPLC.

Benefits of technology

This compound showed good anti-hepatocellular activity, with an IC50 value of 9.17±1.32μM, which is suitable for the preparation of anti-hepatocellular drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115677717B_ABST
    Figure CN115677717B_ABST
Patent Text Reader

Abstract

The present invention discloses Talaromyces sp. ZHS32CGMCC No. 21473, which has been deposited in the General Microbiological Center of China National Committee for the Preservation and Administration of Microbiological Cultures on June 8, 2021. The center is referred to as CGMCC. The address of the center is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing. The deposit number of the strain ZHS32 is CGMCC No. 21473. The compound prepared by the strain ZHS32 has good anti-liver cancer cell activity and can be used to prepare anti-liver cancer drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of natural product extraction, and relates to an anti-tumor compound and a preparation method and application of the compound. Background Art

[0002] Cancer cells are a type of mutated cell and are the source of cancer. Unlike normal cells, cancer cells have three major characteristics: unlimited proliferation, transformation, and easy metastasis. They can proliferate indefinitely and destroy normal cell tissues.

[0003] Cancer is one of the major diseases that affect human health, among which liver cancer is one of the malignant tumors with a rapid increase in morbidity and mortality, and poses the greatest threat to human health and life. Currently, the commonly used anti-tumor drugs mainly include the following categories: alkylating agents, antimetabolites, antibiotics, botanicals, hormones and endocrine drugs, biological therapeutics, traditional Chinese medicine prescriptions, Chinese patent medicines, marine drugs, etc.

[0004] Anti-tumor drugs derived from natural products have the advantages of significant activity, unique structure, and action mechanism different from general small molecule chemotherapeutic drugs. They play a pivotal role in the research and development of anti-tumor drugs. Summary of the invention

[0005] The first object of the present invention is to provide an anti-tumor compound, the structural formula of which is shown in Formula I:

[0006]

[0007] The second object of the present invention is to provide a method for preparing the compound of formula (I), comprising the following steps:

[0008] Talaromyces sp. ZHS32 is activated, fermented in a solid culture medium, extracted with ethyl acetate to obtain a fermentation product, and the compound of formula (I) is separated and purified from the fermentation product.

[0009] The compound provided by the invention has good anti-liver cancer tumor cell activity and is suitable for preparing anti-liver cancer tumor drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0010] Figure 1 For compound (1) 1 H NMR spectrum.

[0011] Figure 2 For compound (1) 13 C NMR spectrum. DETAILED DESCRIPTION

[0012] The following examples are provided for a better understanding of the present invention, but are not intended to limit the present invention. The experimental methods in the following examples are conventional methods unless otherwise specified. The test materials used in the following examples are from conventional biochemical reagent stores unless otherwise specified. The quantitative tests in the following examples were repeated 3 times, and the results were averaged.

[0013] Example 1

[0014] Isolation and identification of strain ZHS32

[0015] 1. Collection and Isolation of Strain ZHS32

[0016] In July 2018, a strain of bacteria was isolated from marine sediments in the East Sea of ​​Zhoushan and named strain ZHS32.

[0017] Strain ZHS32 is a fungus of marine origin.

[0018] 2. Identification of strain ZHS32

[0019] Molecular identification

[0020] The partial sequence of 18S ribosomal RNA of strain ZHS32 is shown in sequence 1 (SEQ ID NO.1) of the sequence listing, and has the highest sequence similarity with GENBANK ACCESSION NO.LC434644.1, with a similarity of 98.59%.

[0021] According to the above identification results, strain ZHS32 belongs to Talaromyces sp.

[0022] 3. Deposit of strain ZHS32

[0023] Strain ZHS32 belongs to Talaromyces sp. and was deposited in the General Microbiology Center of China Culture Collection Administration (CGMCC for short, address: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing) on ​​June 8, 2021, with the deposit number CGMCC No. 21473.

[0024] Example 2

[0025] Preparation of compounds

[0026] Rice culture medium: Soak 200 g of rice in 200 mL of water overnight and sterilize with high pressure steam at 121°C for 30 min.

[0027] PDA medium: Mix 200 g of potato, 20 g of glucose, 15 g of agar and 1000 mL of water, and sterilize with high-pressure steam at 121°C for 30 min.

[0028] 1. Solid fermentation of strain ZHS32

[0029] 1.1 Activation of strain ZHS32

[0030] The strain ZHS32 preserved in the glycerol tube was cultured on the PDA plate for 5 days, and the colonies were allowed to fill the plate.

[0031] 1.2 Solid fermentation of strain ZHS32

[0032] When the colonies fill the plate, place five 3 cm 2 The bacterial blocks of different sizes together with the culture medium were inoculated into a 1000 mL Erlenmeyer flask containing rice culture medium and cultured aseptically at 25°C for 30 days.

[0033] 2. Extraction of Compounds

[0034] 2.1 Add an equal volume of organic reagent (ethyl acetate) to the flask (containing the solid fermentation product) obtained in step 1.2, extract at room temperature for 24 hours, and collect the first supernatant.

[0035] 2.2 Add an equal volume of organic reagent (ethyl acetate) to the conical flask in step 2.1 again, extract at room temperature for 24 hours, and collect the second supernatant.

[0036] 2.3 Add an equal volume of organic reagent (ethyl acetate) to the conical flask in step 2.2 again, extract at room temperature for 24 hours, and collect the supernatant for the third time.

[0037] 2.4 Combine the first supernatant of step 2.1, the second supernatant of step 2.2, and the third supernatant of step 2.3, and distill under reduced pressure to dryness to obtain 19.5 g of crude extract.

[0038] 3. Isolation and purification of compounds

[0039] 3.1 Vacuum silica gel column chromatography to obtain eluent

[0040] The crude extract obtained in step 2.4 was subjected to reduced pressure silica gel column chromatography.

[0041] The column model is: 6×35cm;

[0042] Filling material: Thin layer chromatography silica gel H;

[0043] The elution process is as follows: 500 mL of eluent (composed of 2 parts by volume of petroleum ether and 8 parts by volume of ethyl acetate) is used for elution at a flow rate of 50 mL / min, and the eluent after passing through the column is collected.

[0044] 3.2 The chromatographic eluent is subjected to medium pressure ODS reverse phase column chromatography to obtain reverse phase eluent

[0045] The parameters of the medium pressure reverse phase column chromatography separation are as follows:

[0046] The column model is: 3×50cm;

[0047] Filling material: YMC GEL ODS-A;

[0048] Gradient elution with methanol-water (20% methanol-100% methanol) at a flow rate of 15 mL / min;

[0049] The eluate after passing through the column with a volume of 70% methanol mobile phase was collected to obtain a reverse phase eluate.

[0050] 3.3 Separate the reverse phase eluent by reverse phase HPLC to obtain HPLC eluent

[0051] The parameters of the reversed-phase HPLC separation are as follows:

[0052] The column models were: Reprosil-Pur Basic-C18 (5 μm; 10 × 250 mm);

[0053] The elution process is as follows: gradient elution with 30–65% by volume acetonitrile aqueous solution for 60 min at a flow rate of 2 mL / min.

[0054] The collection retention time was 43.7–44.3 min (the peak retention time t R The eluent after column passage is 44.0 min.

[0055] 3.4 The HPLC eluate collected in step 3.3 was distilled to dryness under reduced pressure to obtain 3.0 mg of product.

[0056] 4. Characterization of Compounds

[0057] The product of step 3.4 was analyzed by organic mass spectrometry and nuclear magnetic resonance spectroscopy.

[0058] The characterization data of the product are as follows:

[0059] Yellow solid;

[0060] Molecular formula: C 23 H 30 O7; molecular weight: 418;

[0061] 1 H NMR spectrum see Figure 1 , 13 C NMR spectrum see Figure 2 ;

[0062] According to the above characterization data, the physicochemical data and the spectrum of the above compounds, the product of step 3.4 is a compound represented by formula (I):

[0063]

[0064] Example 3

[0065] The compound represented by formula (I) has anti-tumor effect.

[0066] The MTS method was used to detect the anti-tumor effect of the compound represented by formula (I).

[0067] Cisplatin was used as a positive control for the compound and parallel experiments were performed.

[0068] The tumor cells used in this example are: human hepatoma cells (HepG2) (purchased from the Medical Cell Center of the Chinese Academy of Medical Sciences).

[0069] The specific steps of the experiment are as follows:

[0070] 1. Cell Recovery

[0071] Take out the frozen human liver cancer cells (HepG2) from liquid nitrogen and thaw them in a 37℃ water bath for 2 minutes. After centrifugation for 2 minutes, discard the supernatant, add RPMI-1640 medium containing 10% fetal bovine serum, gently blow to mix the cells evenly, and transfer them to a 10cm culture dish. Add 10mL of RPMI-1640 medium and place in a 37℃, 5% CO2 cell culture incubator for culture to obtain cell culture fluid.

[0072] 2. Cell Passaging

[0073] Preheat PBS, culture medium, and trypsin at 37°C. Rinse the cell culture medium once with PBS, discard the PBS, add 0.25% trypsin (containing EDTA), and digest at 37°C for 2 minutes. After cell digestion, add a complete culture medium containing serum equal to the trypsin to terminate the trypsin reaction, and gently blow with a pipette to detach the cells from the bottom of the dish to form a single cell suspension for cell counting. Divide into new culture dishes at a ratio of 1:3–1:4, add 10mL of culture medium, and place in a 37°C, 5% CO2 cell culture incubator for culture to obtain passage cells.

[0074] 3. Cytotoxic Activity Detection

[0075] Human hepatoma cells (HepG2) growing in logarithmic phase were taken and counted after digestion. 3×10 3Cells were inoculated into 96-well cell culture plates and cultured overnight at 37°C and 5% CO2. After the cells adhered to the plate, the culture medium was discarded and 100 μL of phenol red-free serum-free DMEM culture medium was added. The compounds and positive controls were dissolved in DMSO and added to the 96-well plate. The final concentrations of the samples to be tested in each group of wells were 100, 50, 25, 12.5, 6.25 and 3.13 μM, respectively. The blank control group was added with an equal volume of organic solvent DMSO, and each group had 3 parallel wells. Incubate for 48 hours at 37°C and 5% CO2. 20 μL of the prepared MTS:PMS mixed solution of 20:1 was added to each well and incubated for 90 minutes at 37°C in the dark.

[0076] 4. Result judgment

[0077] The light absorbance of each well was measured at 490 nm using an enzyme-labeled instrument, the results were recorded, and the inhibition rate was calculated.

[0078] The calculation formula of inhibition rate (%) is: (1-OD 给药组 / OD 空白对照组 )×100%.

[0079] IC calculation using Prism 6.0 software 50 value.

[0080] The effect of the compound represented by formula (I) on human liver cancer cells (HepG2) was tested by repeating three times.

[0081] IC of the compound represented by formula (I) against human liver cancer cells (HepG2) 50 The value was 9.17±1.32μM.

[0082] IC of cisplatin against human hepatocellular carcinoma cells (HepG2) 50 The value was 10.44±1.55μM.

[0083] Conclusion: The compound represented by formula (I) has good anti-liver cancer cell activity and can be used to prepare anti-liver cancer drugs. Sequence Listing <110> Institute of Microbiology, Chinese Academy of Sciences <120> An anti-tumor compound and its preparation method and application <160> 1 <170> SIPOSequenceListing 1.0 <210> 1 <211> 564 <212> DNA <213> Talaromyces sp. <400> 1 ccgcactcgg taatgatcct tccgtagggg gacctgcgga aggatcatta ccgagtgcgg 60 gccctcgcgg cccaacctcc cacccttgtc tctatacacc tgttgctttg gcgggcccac 120 cggggccacc tggtcgccgg gggacgcacg tctccgggcc cgcgcccgcc gaagcgcact 180 gtgaaccctg atgaagatgg gctgtctgag tactgtgaaa attgtcaaaa ctttcaacaa 240 tggatctctt ggttccggca tcgatgaaga acgcagcgaa atgcgataag taatgtgaat 300 tgcagaattc cgtgaatcat cgaatctttg aacgcacatt gcgccccctg gcattccggg 360 gggcatgcct gtccgagcgt catttctgcc ctcaagcacg gcttgtgtgt tgggtgtggt 420 ccccccgggg acctgcccga aaggcagcgg cgacgtccgt ctggtcctcg agcgtatggg 480 gctctgtcac tcgctcggga aggacctgcg ggggttggtc accaccatgt tttaccacgg 540 tgacctcgga tcaggtagga gtct 564

Claims

1. A method for preparing a compound, wherein the structural formula of the compound is as shown below: ; It is characterized in that The following steps are involved: Activated strain ZHS32; the strain ZHS32 is a blue bacteria ( Talaromyces sp . )ZHS32, whose deposit number is CGMCC No.21473; the activated strain ZHS32 is cultured on a PDA plate for 5 days, waiting for the colonies to fill the plate; Solid fermentation strain ZHS32; the solid fermentation strain ZHS32 is 5 3 cm 2 The activated bacterial mass of different sizes and the culture medium were inoculated into a 1000 mL Erlenmeyer flask containing rice culture medium and cultured aseptically at 25°C for 30 days. The solid fermentation product is extracted with ethyl acetate to obtain a crude extract; the solid fermentation product is extracted with ethyl acetate by adding equal volumes of ethyl acetate to the solid fermentation strain ZHS32 three times, extracting at room temperature for 24 hours, combining the supernatants collected three times, and distilling under reduced pressure to dryness; Using vacuum silica gel column chromatography to obtain a chromatography eluent; the vacuum silica gel column chromatography refers to using a mixed solution of 2 parts by volume of petroleum ether and 8 parts by volume of ethyl acetate to perform vacuum silica gel column chromatography on the crude extract; Separate by reverse phase chromatography to obtain a reverse eluent; The separation by reverse phase chromatography refers to the separation of the chromatographic eluent by medium pressure ODS reverse phase column chromatography using a methanol-water mixed solution; The HPLC eluent is separated by reverse phase HPLC; the separation by reverse phase HPLC refers to the reverse phase HPLC separation of the reverse eluent by using an acetonitrile aqueous solution.